Starting from the Department of Clinical Pharmacology and Therapeutics of the Seoul National University College of Medicine,
we have conducted the quantitative bioanalysis for phase 1 clinical studies for over 20 years, contributing to the new drug development in Korea. Since its establishment in 2018 when APACE Inc. was reborn as a clinical study sample analysis institution, the company has performed the analysis for various clinical studies in cooperation with pharmaceutical companies, medical institutions, and contract research organizations (CRO).
APACE Inc. makes earnest efforts to acquire reliable results by paying attention to the voice of the clients, provides education and opportunities to the employees to display their competence as analytical experts, and contributes to new drug development and personalized therapy through insight into the future and spirit of the challenge.

APACE Inc. CEO